N-Terminal Proteolysis of Full-Length Mutant Huntingtin in an Inducible PC12 Cell Model of Huntington’s Disease

Proteolytic cleavage of mutant huntingtin may play a key role in the pathogenesis of Huntington’s disease; however the steps in huntingtin proteolysis are not fully understood. Huntingtin was shown to be cleaved by caspases and calpains within a region between 460-600 amino acids from the N-terminus. Two smaller N-terminal fragments produced by unknown protease have been previously described as cp-A and cp-B. To further investigate the huntingtin proteolytic pathway, we used an inducible PC12 cell model expressing full-length huntingtin with either normal or expanded polyglutamine. This cell model recapitulates several steps of huntingtin proteolysis: proteolysis mediated by caspases within the region previously mapped for caspase cleavage, and cleavage generating two novel N-terminal fragments (cp-1 approximately 90-105 residues long and cp-2 extending beyond 115-129 epitope of huntingtin). Interestingly, the deletion of amino acids 105-114 (mapped previously as a cleavage site for cp-A) failed to affect the production of cp-1 or cp-2. Therefore, we conclude that these new fragments are distinct from previously described cp-A and cp-B. We demonstrate that cp-1 and cp-2 fragments are produced and accumulate within nuclear and cytoplasmic inclusions prior to huntingtin-induced cell toxicity, and these fragments can be formed by caspase-independent proteolytic cleavage of huntingtin in PC12 cells. In addition, inhibition of calpains leads to decreased subsequent degradation of cp-1 and cp-2 fragments, and accelerated formation of inclusions. Further delineation of huntingtin cleavage events may lead to novel therapeutic targets for HD.

[1]  Zhao-Xue Yu,et al.  Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity , 2003, The Journal of cell biology.

[2]  D. Tagle,et al.  Mutant Huntingtin Expression in Clonal Striatal Cells: Dissociation of Inclusion Formation and Neuronal Survival by Caspase Inhibition , 1999, The Journal of Neuroscience.

[3]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[4]  Wei Wei,et al.  Degradation of C/EBPbeta in cultured myotubes is calpain-dependent. , 2006, Journal of cellular physiology.

[5]  M. Kubbutat,et al.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability , 1997, Molecular and cellular biology.

[6]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[7]  M. Chesselet,et al.  Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum , 2001, The Journal of Neuroscience.

[8]  E. Storey,et al.  Role of proteolysis in polyglutamine disorders , 2003, Journal of neuroscience research.

[9]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[10]  D. Rubinsztein Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.

[11]  E. Aylward,et al.  Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). , 1997, Medicine.

[12]  C. Ross,et al.  Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation , 2003, Neuroreport.

[13]  J. Cha,et al.  Mechanisms of Disease: histone modifications in Huntington's disease , 2006, Nature Clinical Practice Neurology.

[14]  C. Ross,et al.  Polyglutamine Repeat Length-Dependent Proteolysis of Huntingtin , 2002, Neurobiology of Disease.

[15]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[16]  M. Hayden,et al.  Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.

[17]  D. Rigamonti,et al.  Calcium-dependent Cleavage of Endogenous Wild-type Huntingtin in Primary Cortical Neurons* , 2002, The Journal of Biological Chemistry.

[18]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[19]  Andreas Matouschek,et al.  Inefficient degradation of truncated polyglutamine proteins by the proteasome , 2004, The EMBO journal.

[20]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[21]  E. Wanker,et al.  Interaction of huntingtin fragments with brain membranes – clues to early dysfunction in Huntington's disease , 2006, Journal of neurochemistry.

[22]  A. Hackam,et al.  Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease , 2004, Cell Death and Differentiation.

[23]  S. Humbert,et al.  Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies , 2006, Cellular and Molecular Life Sciences CMLS.

[24]  A. Hackam,et al.  Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells* , 2000, The Journal of Biological Chemistry.

[25]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[26]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.

[27]  Wei Wei,et al.  Degradation of C/EBPβ in cultured myotubes is calpain‐dependent , 2006 .

[28]  S. Krajewski,et al.  Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration Induced In Vivo by 3-Nitropropionate: Implications for Huntington's Disease , 2003, The Journal of Neuroscience.

[29]  D. Borchelt,et al.  Characterization of Huntingtin Pathologic Fragments in Human Huntington Disease, Transgenic Mice, and Cell Models , 2007, Journal of neuropathology and experimental neurology.

[30]  L. Ellerby,et al.  Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.

[31]  E. Nagata,et al.  Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts , 2005, Neurobiology of Disease.

[32]  C. Ross,et al.  What is the role of protein aggregation in neurodegeneration? , 2005, Nature Reviews Molecular Cell Biology.

[33]  Shihua Li,et al.  Multiple pathways contribute to the pathogenesis of Huntington disease , 2006, Molecular Neurodegeneration.

[34]  J. Roh,et al.  Huntingtin is degraded to small fragments by calpain after ischemic injury☆ , 2003, Experimental Neurology.

[35]  Lu Gan,et al.  Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.

[36]  D. Borchelt,et al.  Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin , 2006, Neurobiology of Disease.

[37]  C A Ross,et al.  Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.

[38]  W. H. Goldmann,et al.  Huntingtin Associates with Acidic Phospholipids at the Plasma Membrane* , 2005, Journal of Biological Chemistry.

[39]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Ronald Wetzel,et al.  Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. , 2004, Molecular cell.

[41]  M. DiFiglia,et al.  Lysosomal proteases are involved in generation of N-terminal huntingtin fragments , 2006, Neurobiology of Disease.

[42]  C. Schwarz,et al.  Wild-Type and Mutant Huntingtins Function in Vesicle Trafficking in the Secretory and Endocytic Pathways , 1998, Experimental Neurology.

[43]  K. Lindenberg,et al.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. , 2002, Molecular cell.

[44]  Dale E. Bredesen,et al.  Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.

[45]  Christopher A Ross,et al.  Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.

[46]  H. Lehrach,et al.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.

[47]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[48]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[49]  R. G. Kulka,et al.  Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae , 1998, The EMBO journal.

[50]  Z. Qin,et al.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  L. Thompson,et al.  Autophagy regulates the processing of amino terminal huntingtin fragments. , 2003, Human molecular genetics.

[52]  J. Mandel,et al.  A cellular model that recapitulates major pathogenic steps of Huntington's disease. , 1998, Human molecular genetics.

[53]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[54]  S. Berman,et al.  Update on huntington’s disease , 2006, Current neurology and neuroscience reports.